Big Pharma Attempts to Undermine Trump's Drug Pricing Legislation
Large pharmaceutical companies are attempting to subvert president's transparency laws
© press
As President Trump pushes for more transparent drug pricing policies within the pharmaceutical industry, Big Pharma is attempting to undermine his administration's efforts.
Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl said on Monday they believe “just including list prices is not sufficient and would be misleading for several reasons.”
According to Ubl, the price information could discourage patients from seeking needed medical attention since list prices rarely reflect what consumers actually pay through insurance.
PhRMA insists that, instead, in-ad links to websites should be provided that would feature a “drug’s list price, an expected range of possible patient out-of-pocket costs and financial support that is available to help consumers pay for their drugs.”
© press
According to Breitbart, PhRMA’s move did not impress Health and Human Services (HHS) Secretary Alex Azar, who does not believe this half-measure is nearly enough:
"The drug industry remains resistant to providing real transparency around their prices, including the sky-high list prices that many patients pay.
"So while the pharmaceutical industry’s action today is a small step in the right direction, we will go further and continue to implement the president’s blueprint to deliver new transparency and put American patients first."
With HHS putting its proverbial foot down, PhRMA is already indicating that it will mount a First Amendment legal challenge.
“The concern is that if the government is compelling companies to speak, then that violates the First Amendment,” PhRMA General Counsel James Stansel said.
© press
Harvard Medical School lawyer Ameet Sarpatwari sees that as a weak rebuttal.
“Industry could challenge the proposal as unconstitutional compelled commercial speech, but it is doubtful that such a challenge would be successful,” he said.
“A strong argument exists that list prices are factual, uncontroversial information, in which case HHS would need only to show that the disclosure requirement is rationally related to legitimate government interest.”
With the administration likely to make an announcement about the guidelines this week, it looks like the pharmaceutical industry will face an uphill battle if it wants to keep its price tags hidden from the public eye.
